Samantha E. Greenberg, MS, MPH, CGC, a genetic counselor at the Huntsman Cancer Institute, on when to discuss genetic testing with prostate cancer patients.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.